101 results about "Colony formation" patented technology

Aspects of the present disclosure relate to a method of colony enumeration. The method includes identifying colony forming units of microorganisms in a combined image using a pretrained deep learning model on a colony enumeration device. The method can include providing a plurality of identification characteristics of the colony forming units to an interaction component such that the interaction component can project at least some of the plurality of identification characteristics onto the combined image.

The invention relates to the fields of epigenetic regulation and tumor treatment, and aims to evaluate that the cell distribution of the mutant is consistent with that of H3 by constructing Bas-2B (H3K9R) and Bas-2B (H3K18R) stably transfected cell strains and analyzing the cell positioning condition of the H3K9R / H3K18R mutant through an immunofluorescence technique. According to the present invention, a Western blotting technology is adopted to detect the H3K9 / H3K18 lactic acid modification level of Bas-2B (H3K9R) and Bas-2B (H3K18R) cells compared to control cells so as to verify the influence of the H3K9R / H3K18R mutant on the H3K9 / H3K18 lactic acid modification; after Bas-2B (H3K9R), Bas-2B (H3K18R) cells and control cells of the Bas-2B (H3K9R) and the Bas-2B (H3K18R) cells are subjected to nickel compound exposure treatment, the influence of the H3K9R / H3K18R mutant on the nickel compound induced lung cancer is evaluated through a soft agar cloning formation experiment. An AGS cell line stably transfecting H2BK16R is constructed, and the cell localization condition of the H2BK16R mutant is analyzed through an immunofluorescence technology. According to the present invention, a Westernbloting technology is adopted to detect the lactic acid modification level of AGS (H2BK16R) cells so as to verify the influence of the H2BK16R mutant on the H2BK16 lactic acid modification; the influence of the H2BK16R on the malignant proliferation ability of the gastric cancer is researched through a soft agar clone formation experiment.

A dry stable probiotic composition is provided. The composition comprises one or more viable probiotic microorganisms, one or more hydrolyzed proteins, one or more disaccharides, one or more oligosaccharides, and one or more polysaccharides, but not trehalose. The composition has viability of at least 1×1010 CFU / g, and a viability loss of less than 1 log unit / g after one month at a temperature of 40° C. and a relative humidity of 33%. Also provided are methods for preparing the dry stable probiotic composition.

This invention provides a 2-sulfonylpyrimidine-4-amide compound and its uses, belonging to the field of antitumor drug technology. The compound of this invention exhibits excellent antitumor activity targeting the colchicine site of tubulin, demonstrating antiproliferative activity against tumor cells such as HeLa, HepG2, H1299, and MCF-7 at the micromolar level, and significantly inhibiting colony formation in a dose-dependent manner. Furthermore, the compound inhibits tubulin polymerization and disrupts the microtubule network of H1299 cells in vitro, inducing cell cycle arrest in the G2 / M phase and apoptosis. More importantly, the compound can inhibit angiogenesis in HUVECs in vitro. The compound of this invention has great potential in the preparation of microtubule destabilizing agents targeting the colchicine site.

The application relates to the field of biological medicine, and particularly relates to application of a TMEM119 gene or protein in development of an anti-gastric cancer drug, and particularly to application of a TMEM119 inhibitor in preparation of an anti-gastric cancer drug, wherein the inhibitor can be a small-molecule nucleotide for targeted knockdown of the TMEM119 gene or protein, the small-molecule nucleotide is shRNA or siRNA, the shRNA is a double-stranded oligonucleotide composed of complementary base sequences shown in SEQ ID NO. 1-2 or SEQ ID NO. 3-4; and the siRNA has a guide strand with a base sequence shown in SEQ ID NO. 7 or SEQ ID NO. 8. Experiments prove that when the expression of the TMEM119 gene of human gastric cancer cells is knocked down, the viability and the colony formation ability of the human gastric cancer cells are significantly reduced, thereby inhibiting the proliferation and survival of the gastric cancer cells, and further achieving the effect of restraining the occurrence, development, recurrence or metastasis of the gastric cancer.

The present invention provides the use of fangchinoline in preparing a drug for treating STAG2 mutation acute myeloid leukemia, and relates to the field of leukemia therapeutics. The use of fangchinoline in preparing a drug for treating STAG2 mutation acute myeloid leukemia according to the present invention addresses the problems of high incidence, poor prognosis and lack of effective drugs in STAG2 mutation acute myeloid leukemia. Fangchinoline can inhibit the proliferation and colony formation of AML cell lines SKM-1, Kasumi-6, THP-1 and U-937, induce apoptosis, cell cycle arrest and cell differentiation in these cells, and thus exert an anti-STAG2 mutation acute myeloid leukemia effect.

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a non-human animal. These methods include administering intratumorally to the non-human animal a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×106-1×1010 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a non-human animal, a method for microscopically precise excision of tumor cells in a non-human animal, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a non-human animal, methods for ablating a solid tumor present in a non-human animal, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a non-human animal are also provided.

The invention relates to application of an IP6 synthesis related kinase inhibitor in tumor radiotherapy sensitization. According to the application, CRISPR / Cas9 is used in vitro for screening important kinases in cells, it is found that the important kinases IPPK and ITPK1 participating in IP6 synthesis are related to radiotherapy sensitivity, and the research value of IPPK and ITPK1 serving as radiotherapy sensitization targets is further verified through cell colony formation experiments, mouse tumor-bearing induced radiotherapy tolerant cells and patient transcriptome data. In the aspect of mechanism and effect, it is found that targeted inhibition of IPPK and ITPK1 can promote lipid peroxidation induced by Fenton reaction by improving the level of free ferrous ions, so that ferroptosis is easier to occur, and sensitization can be achieved on radiotherapy which also causes lipid peroxidation. The invention provides a potential strategy for comprehensive treatment of malignant tumors, and has important practical significance for formulation of an accurate treatment scheme of malignant tumors clinically.

The invention discloses a synthetic microbial flora for improving pork quality and application thereof. The synthetic microbial flora comprises two kinds of probiotics, namely lactobacillus plantarum WY2401 with the preservation number of CCTCC (China Center For Type Culture Collection) NO. The invention relates to ackermann muciniophilic bacteria. The synthetic microbial flora is prepared by compounding lactobacillus plantarum and ackermann mucophile according to a colony formation unit number ratio of 1: 1, concentrating and freeze-drying. Experimental results show that the synthetic microbial flora is added into the basic feed of the fattening pigs, so that the carcass traits are improved, the intramuscular fat content is increased, the conversion of muscle fiber types and the development of muscle fibers are promoted, and the meat quality is improved.

This useful solution, in the field of biotechnology and regenerative medicine, relates to a process for enhancing the efficiency of induced pluripotent stem cell (iPSC) colony formation from human peripheral blood mononuclear cells (PBMCs). The solution aims to overcome the low reprogramming efficiency, unstable colony formation, and limited iPSC cloning rates commonly encountered in PBMC iPSC generation processes. The technical essence of the solution lies in the synchronized optimization of the reprogramming process, including pre-activating PBMCs with an appropriate cytokine combination at predetermined times before reprogramming, using a non-integrated Sendai virus system under optimized transformation conditions, switching culture media at defined intervals to promote cell state transitions, and applying a selection, enrichment, and stabilization process for iPSC cloning in the initial passages after colony formation.The process also incorporates cell line quality control steps through assessment of residual Sendai virus RNA removal and mycoplasma contamination testing during line maintenance. Experimental results show that the proposed process increases the number of iPSC colonies formed, improves the rate of establishing stable iPSC lines, and enhances cell homogeneity and pluripotency maintenance. The solution can be applied in basic research, pathogenesis modeling, drug screening, regenerative medicine, and studies using induced pluripotent stem cells derived from human peripheral blood cells.

The application provides application of glutaroyl-CoA dehydrogenase in inducing ferroptosis of liver cancer cells, and belongs to the technical field of biotechnology.The application provides application of glutaroyl-CoA dehydrogenase (GCDH) in preparing products for evaluating risk of liver cancer and evaluating prognosis risk of liver cancer, and the tumor stage and T grade can be estimated by detecting the expression amount of GCDH, and the survival effect of liver cancer patients is evaluated.The application provides application of the overexpression reagent of GCDH in preparing products for inhibiting proliferation of liver cancer cells and inducing ferroptosis of liver cancer cells, and the ferroptosis of liver cancer cells is promoted by overexpressing GCDH in cells, and the colony formation ability of liver cancer cells is reduced.Further, the application provides application of the overexpression reagent of GCDH combined with a CA9 inhibitor in preparing products for inhibiting proliferation of liver cancer cells.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an ITGA6 inhibitor in preparation of a medicine for treating uveal melanoma. By integrating bioinformatics analysis of databases of TCGA, GTEx, CPTAC and the like, the invention systematically reveals that the ITGA6 has high specific expression in uveal melanoma and is significantly related to poor prognosis of a patient for the first time. In-vitro experiments prove that by knocking down ITGA6, proliferation, migration, invasion and colony forming ability of UVM cells can be effectively inhibited. According to the invention, small molecular compounds such as 4.5-diphenyl-1H-imidazole, MS-275, W-13 and the like and siRNA (small interfering Ribonucleic Acid) targeting ITGA6 are screened out to be used as effective inhibitors, and specific drug dosage forms such as intraocular injection and the like are provided. In addition, the ITGA6 inhibitor can be used in combination with a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor or a chemotherapeutic drug to generate a synergistic anti-tumor effect. Mechanism research shows that ITGA6 promotes UVM progress by regulating a signal channel and a tumor immune microenvironment. The invention provides a new targeted treatment strategy for uveal melanoma, and has important clinical application value.

The present invention discloses a semicarbazide derivative and its preparation method and application, which belongs to the technical field of anti-lung cancer targeted drugs. The semicarbazide derivative of the present invention can inhibit the growth of H1299 cells in a dose-dependent manner, but has little toxicity to normal lung epithelial cells BEAS-2B. The semicarbazide derivative of the present invention can significantly inhibit the cloning of non-small cell lung cancer cells A549 and H1299, so it has a significant inhibitory effect on the proliferation of non-small cell lung cancer. The semicarbazide derivative provided by the present invention can inhibit the protein expression of GPX4 in non-small cell lung cancer A549 cells, and by inhibiting the protein expression of GPX4, promote the ferroptosis of non-small cell lung cancer cells, thereby playing a role in suppressing tumors.

This invention provides a human embryonic stem cell expansion culture medium, comprising DMEM / F12 medium, ITS-A, HEPES, magnesium ascorbate phosphate, non-essential amino acids, bFGF, FGF2-G3, GlutaMAX, LY-333531, gentamicin sulfate, Y27632, and CHIR99021. Y-27632 inhibits pluripotent stem cell apoptosis, improves adhesion efficiency, maintains pluripotency and colony formation ability; CHIR99021 enhances the self-renewal of pluripotent stem cells and inhibits their differentiation; LY-333531 inhibits spontaneous differentiation of pluripotent stem cells; and gentamicin sulfate reduces the risk of contamination during culture. The culture medium provided by this invention is serum-free, free of allogeneic substances, has a simple composition, and offers excellent expansion speed, effectively maintaining long-term stable passage of human embryonic stem cells, providing stable technical support for scientific research.

The invention relates to the technical field of biological medicine, in particular to a polypeptide inhibitor of a targeted MZF1 gene and application of the polypeptide inhibitor in colon cancer treatment, and a polypeptide compound named as 10PANX ACETATE is the first MZF1 gene efficient targeted inhibitor which is clearly recognized and has high uniqueness and innovativeness. In the field of biological medicines, the compound fills the blank of medicines for treating diseases caused by abnormal expression of MZF1. Through rigorous in-vitro and in-vivo animal experiments, the 10PANX ACETATE shows a remarkable inhibition effect on MZF1 overexpression cells, including inhibition of cell viability, proliferation and clone formation ability and down-regulation of MZF1 protein expression, and the 10PANX ACETATE shows a remarkable inhibition effect on MZF1 overexpression cells. In addition, the compound has a remarkable curative effect on the living body level, is high in safety and has no obvious toxic or side effect. Therefore, the 10PANX ACETATE provides a brand new drug candidate for prevention and treatment of MZF1 overexpression related diseases such as colon cancer, and has important clinical application value and wide market prospect.

According to the isolated culture identification and key marker detection method for the down producing goat hair follicle stem cells, trypsin and EDTA are used for jointly digesting skin tissue, and high-activity cells are efficiently obtained; a culture medium containing various growth factors is adopted for culture, and cell proliferation and stemness maintenance are promoted. And identifying and integrating morphological observation, growth curve determination and clone formation experiment to accurately judge the characteristics of the cells. Immunofluorescent staining and real-time fluorescent quantitative PCR are applied to key marker detection, and expression of markers such as CK15, CD34 and beta1 integrin is detected with high sensitivity. The method is high in separation efficiency, accurate in identification and sensitive in marker detection, can provide sufficient high-quality cells for the research on the hair follicle stem cells of the cashmere goat, assists in deeply understanding the biological characteristics and the regulation mechanism of the cells, and is of great significance for improving the yield and quality of cashmere and promoting the development of related biotechnologies.

The application relates to the technical field of pharmaceutical chemistry, and discloses a sulfuryl hydrazone compound, a preparation method thereof and anti-tumor application. The compound is synthesized from isatin derivatives and sulfuryl hydrazine through two-step nucleophilic substitution-elimination reaction, has a chemical structure as shown in formula (I), and is characterized by 1H NMR, 13C NMR and HRMS. The sulfuryl hydrazone compound has significant inhibitory activity on A549 (lung cancer), HepG2 (liver cancer) and Hela (cervical cancer) three human cancer cell strains, the value of some compounds is as low as 0.03 micromole / L, the compound can induce cell apoptosis by mediating ROS generation in tumor cells, inhibiting the NF-kappa B signal pathway and activating Caspase-3 activity, and can effectively inhibit cancer cell migration and colony formation. The compound has a mild synthesis process, simple operation and wide substrate applicability, can be used as a potential anti-tumor active ingredient, can be used for preparing drugs for resisting lung cancer, liver cancer, cervical cancer and other tumors, and can provide new candidate compounds and technical support for cancer treatment.

The invention discloses an HMGB3 inhibitor and application of the HMGB3 inhibitor in preparation of a medicine for treating liver cancer, and relates to the field of molecular biology and biological medicine. The application has the advantages that HCC cell proliferation and clone formation are inhibited through HMGB3shRNA, so that HCC transplanted tumor growth is inhibited, HMGB3 is knocked down to up-regulate expression of TNF, NFKBIA and other genes and down-regulate expression of CARD11 and other genes, NF-kappa B nuclear translocation degradation IKK is further inhibited, in-vitro proliferation and invasion ability of hepatocellular carcinoma cells can be seriously affected, development of liver cancer can be inhibited, and the application has a good application prospect. The compound can be used for preparing anti-hepatoma drugs.

This invention relates to the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia, belonging to the field of biomedical technology. To address the problem that traditional AML treatment targets lack tumor specificity and fail to meet clinical needs, this invention provides the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia. This invention demonstrates that PWWP2B is highly expressed in acute myeloid leukemia (AML) cells, and as a molecular marker, it can accurately distinguish AML from healthy individuals or non-leukemia patients. In vivo and in vitro experiments demonstrate that knocking out PWWP2B can significantly inhibit the proliferation and colony formation of AML cells, promote their differentiation and apoptosis, and inhibit the activity of leukemia cells in patients. This invention also reveals for the first time a novel use of the small molecule compound EZM0414 in the treatment of AML and its synergistic effect when used in combination with methyltransferase inhibitors.

This invention discloses the application of total paeoniflorin in the preparation of drugs for the treatment of head and neck squamous cell carcinoma, belonging to the field of biomedical technology. Addressing the bottlenecks in current treatments for head and neck squamous cell carcinoma, such as high toxicity of radiotherapy and chemotherapy, low response rates to immunotherapy, and easy resistance to targeted drugs, this invention provides a method for preparing total paeoniflorin and a drug-loaded preparation technology based on hydrogels obtained from modified chitosan. Total paeoniflorin can dose-dependently inhibit the proliferation rate, colony formation ability, and in vitro migration ability of SCC7, FADU, and CAL27 head and neck squamous cell carcinoma cell lines, and significantly induce apoptosis. This invention utilizes the multi-target effects of total paeoniflorin to exert anti-head and neck squamous cell carcinoma effects through modulation of the tumor microenvironment and enhancement of immune surveillance. Furthermore, the loaded drug exhibits good sustained-release properties and biosafety, providing a new, highly effective, and low-toxicity strategy for the treatment of head and neck squamous cell carcinoma, and has significant clinical application value.

The invention relates to the technical field of biological medicine, in particular to application of a steroid compound shown in a formula I in preparation of anti-hepatoma drugs. The application finds that medoxone can significantly inhibit malignant growth, plate clone formation ability and apoptosis promoting ability of liver cancer cells MHCC97H through research for the first time, and further finds that the binding affinity of medoxone and TDP-43 protein is relatively high, and medoxone can significantly inhibit expression of the TDP-43 protein along with increase of drug concentration, so that medoxone has a very good anti-liver cancer effect.

This invention relates to the field of biomedical technology, and in particular to the application of hD1R protein in the preparation of drugs for the treatment of AML. Addressing the current lack of systematic and in-depth research on whether hD1R protein can directly act on AML cells and whether it has a synergistic effect with existing standard chemotherapy drugs (such as anthracyclines), this invention, through a series of in vivo and in vitro experiments and the construction of a NOD / SCID mouse transplantation model, confirms that hD1R protein alone can effectively inhibit AML cell proliferation, induce apoptosis, inhibit AML cell colony formation, and downregulate the expression of the key anti-apoptotic gene Bcl2 in AML cells. It also confirms that hD1R treatment can significantly prolong the survival of model mice. Furthermore, by setting up a Dox+hD1R group (combined experimental group), it is confirmed that when hD1R protein is used in combination with anthracycline chemotherapy drugs, it exhibits significant synergistic effects in inhibiting AML cell proliferation, promoting AML cell apoptosis, downregulating the expression of the anti-apoptotic gene Bcl2 in AML cells, and inhibiting AML cell colony formation.

The invention provides an application of FGF4 (fibroblast growth factor 4) as a drug target in treatment of enameloblastoma, relates to the technical field of biological medicines, finds a potential effect of the FGF4 in the enameloblastoma for the first time, proves an inhibition effect of the FGF4 on tumor growth, proves that the FGF4 can be used as a treatment target of the enameloblastoma, and proves that the FGF4 gene is knocked down in an enameloblastoma cell line, so that the treatment effect on the enameloblastoma is obviously improved. Cell proliferation, cell migration, cell invasion and cell colony formation can be inhibited; in an animal body, the FGF4 gene is knocked down to inhibit the growth of the enameloblastoma, which shows that the FGF4 has the effect of regulating and controlling the growth of the enameloblastoma, and the FGF4 inhibitor can inhibit the proliferation, migration, invasion and cell colony formation of an enameloblastoma cell line and inhibit the growth of the enameloblastoma. A new treatment target is provided for prevention and / or treatment of the glamoblastoma, and the application has a wide clinical application value.

The present invention discloses the application of RGS14 in the preparation of a kit for the auxiliary diagnosis or prognosis of liver cancer and the application of an RGS14 expression inhibitor in the preparation of a drug for treating liver cancer. The present invention discovers for the first time that the expression of RGS14 in liver cancer is significantly increased compared with that in adjacent tissues, and the high expression of RGS14 is not conducive to the overall survival of liver cancer patients; and when RGS14 is knocked down, the colony formation and migration of liver cancer cells are significantly inhibited. The high expression of RGS14 is closely related to the poor prognosis of liver cancer patients, suggesting that RGS14 can be used as a prognostic marker for liver cancer, providing effective information for the prognostic evaluation and efficacy monitoring of liver cancer. The present invention also provides an RGS14 expression inhibitor siRNA, which has good interference effect when used for inhibiting the expression of RGS14 and has potential for clinical application.

The present disclosure provides uses of a core promoter of a CREPT gene in the treatment of tumors. The invention provides any application of the following (i)-(ii): (i) application of a core promoter of a CREPT gene as a target spot in preparation of a medicine for treating tumors; and (ii) a use of a reagent targeting a core promoter of a CREPT gene in the preparation of a drug for treating tumors. It is found that the CREPT gene core promoter can be applied to tumor treatment, tumor cell proliferation, tumor clone formation, tumor generation and tumor growth can be inhibited by inhibiting (such as knocking out) the gene core promoter, and the CREPT gene core promoter has important significance on tumor treatment.

This invention discloses the role of the small molecule compound RX4 in the preparation of anti-colon cancer drugs. The structure of RX4 is shown in Figure (1). Our experimental results show that RX4 can inhibit the proliferation and colony formation of colon cancer cell lines RKO, HCT-116, and SW620 in a concentration-dependent manner, inhibit cell migration, and induce apoptosis, thereby achieving anti-tumor biological activity.

The invention discloses application of 2-hydroxycinnamic acid in treatment of gastric cancer, according to the application, the influence of supernate of lactobacillus salivarius or lactobacillus crispatus on gastric cancer cell apoptosis is detected through a flow technology, and the 2-hydroxycinnamic acid is found to be capable of promoting the gastric cancer cell apoptosis and inhibiting the activity of gastric cancer organs. A metabolite in a supernatant of lactobacillus salivarius CICC23175 or lactobacillus crispatus CGMCC1.2743 screened by non-target metabolite omics contains 2-hydroxycinnamic acid, and the gastric cancer cytotoxic resistance of 2-hydroxycinnamic acid is deeply studied to find that the 2-hydroxycinnamic acid not only has the effects of inhibiting gastric cancer cell proliferation, colony formation and cell migration, but also has the effects of inhibiting gastric cancer cell proliferation, colony formation and cell migration. In addition, the 2-hydroxycinnamic acid can also increase the proportion of cells in a G1 / G0 period of a cell cycle, promote apoptosis of gastric cancer cells, and find that the inhibition effect of the 2-hydroxycinnamic acid on proliferation of gastric cancer organs is integrally higher than that of normal gastric epithelium organs.

The invention belongs to the technical field of biological cell visual detection, and particularly relates to a method for detecting the proliferation capacity of cells in a three-dimensional porous microcarrier material, which comprises the following steps: respectively preparing a cell suspension and a porous microcarrier material filled with a complete culture medium solution, uniformly mixing and culturing; digesting the microcarrier material; cleaning, filtering and collecting the microcarrier material gathered above the screen; preparing a low-melting-point agarose solution, uniformly mixing the low-melting-point agarose solution with the complete culture medium solution to serve as a bottom culture plate / observing and monitoring the cooling temperature of the solution; uniformly mixing a low-melting-point agarose solution with the cooling temperature of 38 + / -2 DEG C and a microcarrier material, and inversely placing above the bottom culture plate to form a middle layer; adding a complete culture medium solution to the upper surface of the middle layer to form a liquid nutrient moisturizing layer; placing the culture material in an incubator, and standing and culturing; and the proliferation activity of the cells in the microcarrier material is judged by calculating the formation rate of the microcarrier cell colonies.

Provided are a cow milk-derived stem cell, and an isolation and culture method therefor. The method comprises the following steps: (1) taking fresh cow milk, and isolating cells therefrom; (2) coating a culture dish with a matrix gel in advance, discarding the coating solution, then washing the culture dish with a washing solution, and discarding the washing solution; (3) inoculating the cells treated in the step (1) on the coated culture dish, and culturing the cells with a stem cell culture medium; and (4) when the cell confluence reaches 80% or more, digesting the cells with a digestion enzyme, terminating the digestion, isolating the cells, resuspending the cells using a CTFR culture solution, then inoculating the cells on a feeder layer for culture, promoting colony formation, and performing subculture to obtain cow milk-derived stem cells. The cow milk-derived stem cell has OCT4, SOX2, NANOG and SSEA4 markers.